{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.7"},{"groupId":"OG001","value":"9.8"}]}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.1"},{"groupId":"OG001","value":"9.8"}]}],"title":"Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"Adapted ACR Pediatric 30 criteria determined responders (improved from baseline of at least 30% in at least 3 response variables 1-6 and no intermittent fever in preceding week \\[variable 7\\], with no more than one variable 1-6 worsening \\> 30% ) 1. Physician's Global Assessment of disease activity: 0-100 mm VAS 2.Parent/Patient's Global Assessment of Patient's overall wellbeing: 0-100mmVAS in Child Health Assessment Questionnaire (CHAQ) 3. Functional ability: CHAQ 4.Number of joints with active arthritis 5. Number of joints with limited of motion 6. Laboratory measure of inflammation CRP (mg/L)","groups":[{"description":"Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients\\>37.5 kg) received two sc injections.","id":"OG000","title":"Canakinumab"},{"description":"Patients received a single dose matching placebo of canakinumab on day 1.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) consisted of all randomized patients who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 15, Day 29","title":"Percentage of Patients Who Meet the Adapted American College of Rheumatology (ACR) Pediatric 30 Criteria","type":"PRIMARY","unitOfMeasure":"percentage of participants"}